BiotechTube

Moxifloxacin 400 mg

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Side-effect of Antibiotic

Conditions

Side-effect of Antibiotic

Trial Timeline

Jul 1, 2008 → Jul 1, 2010

NCT ID
NCT01302951

About Moxifloxacin 400 mg

Moxifloxacin 400 mg is a approved stage product being developed by Bayer for Side-effect of Antibiotic. The current trial status is completed. This product is registered under clinical trial identifier NCT01302951. Target conditions include Side-effect of Antibiotic.

Hype Score Breakdown

Clinical
20
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01302951ApprovedCompleted